rTMS for Treatment of Depressed Phase of Bipolar Disorder Type II

Bipolar Disorder Clinical Trial

— rTMS  

Official title:

rTMS (Repetitive Transcranial Magnetic Stimulation) for Acute Treatment of Depressed Phase of Bipolar Disorder Type II

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00447096
• Other study ID #: 102006-040
• Status: Withdrawn
• Phase: Phase 2
• First received: March 12, 2007
• Last updated: June 8, 2016
• Start date: February 2007
• Est. completion date: February 2010

Study information

• Verified date: June 2016
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This research study evaluates an experimental device for the treatment of the depressed phase of Bipolar Disorder Type II. Repetitive Transcranial Magnetic Stimulation (rTMS) is an experimental procedure where a device delivers an alternating magnetic field to a focal area of the brain. When the coil is placed against the scalp on the left frontal area of the head, the magnetic field is focused to a region of the brain that is thought to be involved in depression. This study is intended to test if rTMS can affect this region of the brain in a way that improves the symptoms of depression related to Bipolar Disorder Type II. The purpose of this study is to obtain safety and efficacy information regarding the use of rTMS(Repetitive Transcranial Magnetic Stimulation) for patients in the depressed phase of Bipolar Disorder Type II.

Description:

This is a double-blind randomized controlled trial of rTMS for outpatients in the depressive phase of BD-II. Participants will be evaluated at UT Southwestern Medical Center at Dallas. Forty eligible subjects will be randomized to either active treatment (n=20) or sham (no stimulation, n=20). Each subject will receive treatment 5 days per week for a total of 6 weeks. At the end of the 6 weeks, those who remain depressed will have the option of receiving 6 additional weeks of open rTMS treatment. We require these participants to meet the same eligibility criteria in the open phase (i.e. MADRS ≥15, YMRS <12) as in the initial double blind phase. At the completion of treatment, a follow-up appointment will be scheduled with a study physician to ensure that the participant is properly transitioning to clinical care and is not having a significant change in clinical status. Those who do not already have a treating physician will be referred to a new provider.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2010
• Est. primary completion date: February 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male and female outpatients aged 18-55 years old

• Meet DSM-IV criteria for Bipolar Affective Disorder Type II, depressed phase without psychosis as determined by Structured Clinical Interview for DSM-IV

• A MADRS = 15 at Initial Visit, and at Prior to TMS Evaluation

• A Young Mania Rating Scale < 12 at Initial Visit and at Prior to TMS Evaluation

• Duration of current episode of depression >2 months but = 1 year of unsuccessful treatment

• On stable medication and/or psychotherapy for 1 month and clinically appropriate to maintain for duration of trial

• Cognitively intact (Folstein MMSE score >24).

• Clinically competent to give informed written consent

Exclusion Criteria:

• History of epilepsy or seizure disorder, mass brain lesions, cerebrovascular accident, metal in the skull, a history of major head trauma, or any neurologic condition likely to increase risk of rTMS.

• Suicidal risk that precludes safe participation defined as score of 5 or 6 on MADRS item 10 Suicidal Thoughts or clinical impression that the subject is at significant risk for suicide.

• History of any DSM-IV Axis I diagnosis other than Bipolar Affective Disorder Type II, depressed phase, simple phobia and generalized anxiety disorder (GAD) in the last year

• Lifetime history of schizophrenia, schizoaffective, or other psychotic disorder, bipolar disorder type I, dementia, dissociative disorders, and sexual and gender identity disorder

• Personality disorder that makes participation in the trial difficult

• Greater than or equal to 8 episodes of mood disturbance in the previous 12 months

• Greater than 4 unsuccessful treatments in current episode

• History of Substance Abuse or Dependence (DSM-IV) in the last year except nicotine and caffeine

• Positive urine drug test during screening

• Taking any medication that significantly lowers the seizure threshold (e.g. lithium, stimulants, bupropion, TCAs, antipsychotics, theophylline, etc.)

• Unstable medical conditions that precludes safe participation in rTMS treatment trial

• Known or suspected pregnancy

• Women of child-bearing potential not using medically accepted form of contraception when engaged in sexual intercourse

• Any metal or device implants that would increase risk of rTMS

• Unable to determine the motor threshold in the subject

• History of Vagus Nerve Stimulation

• Currently in another investigational study

• Prior electroconvulsive therapy failure

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bipolar Disorder

Intervention

Device:
• Repetitive Transcranial Magnetic Stimulation (rTMS)
Repetitive transcranial magnetic stimulation (rTMS).

Locations

Country	Name	City	State
United States	UT Southwestern Medical Center at Dallas	Dallas	Texas

Sponsors (3)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center	Neuronetics, Stanley Medical Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	QIDS-C (Quick Inventory of Depressive Symptomatology-Clinical Rated)		3 year	Yes
Secondary	MADRS(Montgomery Asberg Depression Rating Scale)		3 year	Yes
Secondary	IDS-C (Inventory of Depressive Symptomatology- Clinician Rated)		3 year	Yes
Secondary	QIDS-SR (Quick Inventory of Depressive Symptomatology-Self Report)		3 year	Yes
Secondary	YMRS (Young Mania Rating Scale)		3 year	Yes
Secondary	Neuropsychological Testing		3 year	Yes
Secondary	rTMS safety/adverse events		3 year	Yes